NCT04225117: A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed or relapsed on at least 1 prior cytotoxic regimen (taxane or anthracycline) in the metastatic setting and NBC patients must have also progressed on anti-PD-1/L1 treatments
Exclusions: Patients with active unstable central nervous system (CNS) metastases that require treatment – see trial for details; Patients with leptomeningeal disease; Patients who received more than 2 prior lines of cytotoxic therapy in the metastatic setting; Patients with prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates
https://ClinicalTrials.gov/show/NCT04225117

Comments are closed.

Up ↑